$AWHL 8-K/A SEC Filings

THIS SEPARATION AGREEMENT AND GENERAL RELEASE (the “Agreement and General Release”) is made and entered into on June 27, 2026, by and between Michael Buhle (“Executive”) and Aspira Women’s Health Inc., a Delaware corporation (the “Compan...

Certain confidential information contained in this exhibit have been omitted by means of redacting a portion of the text and replacing it with [REDACTED], pursuant to Regulation S-K Item 601(b)(10) of the Securities Act of 1933, as amend...

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UN...

This Securities Purchase Agreement (this “Agreement”) is dated as of January 24, 2024, between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, includi...

Continued growth trend with second quarter revenue of $2.5 million, an increase of 23% over the second quarter of 2022.

On January 10, 2023, Aspira Women's Health Inc. will be presenting to investors. A copy of the investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K filing.

On December 15, 2022, James T. LaFrance resigned from the board of directors (the “Board”) of the Company, effective immediately. Following Mr. LaFrance’s resignation, the Board appointed Dr. Robert Auerbach to the Audit Committee of the...